SCM
FULC icon

Silverarc Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Silverarc Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.01M Hold
391,900
– – 0.31% 51
2025
Q4 		$4.43M Buy
+391,900
New +$3.99M 0.62% 43

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Silverarc Capital Management's FULC Position: Q1 2026 in Review

Silverarc Capital Management increased its Fulcrum Therapeutics (FULC) stake by 6.4% in Q1 2026, buying an estimated $235K and bringing the position to 419,949 shares worth $3.22M. The position accounts for 0.33% of the portfolio, ranked #50.

Silverarc Capital Management first reported a position in FULC in Q4 2020 and has held it in 7 quarters since. The position peaked at $5.24M in Q3 2021. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Silverarc Capital Management held 419,949 shares of Fulcrum Therapeutics worth $3.22M as of Q1 2026.
  • Silverarc Capital Management bought 25,299 Fulcrum Therapeutics shares in Q1 2026, an estimated $235K.
  • Fulcrum Therapeutics made up 0.33% of Silverarc Capital Management's portfolio in Q1 2026, its #50 holding.
  • Silverarc Capital Management first reported a position in Fulcrum Therapeutics in Q4 2020 and has held it in 7 quarters since.
  • Silverarc Capital Management's Fulcrum Therapeutics position peaked at $5.24M in Q3 2021.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.